Evidence map›Paper›PMID 39145929›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2024

Phosphorylation of Insig-2 mediates inhibition of fatty acid synthesis by polyunsaturated fatty acids.

Jing Tian, Joseph L Goldstein, Shili Li, Marc M Schumacher, Michael S Brown

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. PUFAs regulate SREBP1c through phosphorylation of Insig2.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Jing TianDepartment of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, TX 75390.ORCID 0000-0001-9916-650X
Joseph L GoldsteinDepartment of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, TX 75390.ORCID 0000-0002-1894-9463
Shili LiDepartment of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, TX 75390.ORCID 0000-0002-5483-7506
Marc M SchumacherDepartment of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, TX 75390.ORCID 0000-0002-5527-4215
Michael S BrownDepartment of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, TX 75390.ORCID 0000-0002-1324-152X

Funding

Tissue Culture & Antibody Production CoreP01HL160487 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI Helen Haskell Hobbs · 2022 to 2026
$14.9M
UT Southwestern NORCP30DK127984 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI Jeff G McDonald · 2022 to 2026
$7.4M
HHS | NIH (NIH) P01HL160487NHLBI NIH HHS P01 HL160487NIDDK NIH HHS P30 DK127984
6 · The paper itself

Abstract

Insig-1 and Insig-2 are endoplasmic reticulum (ER) proteins that inhibit lipid synthesis by blocking transport of sterol regulatory element-binding proteins (SREBP-1 and SREBP-2) from ER to Golgi. In the Golgi, SREBPs are processed proteolytically to release their transcription-activating domains, which enhance the synthesis of fatty acids, triglycerides, and cholesterol. Heretofore, the two Insigs have redundant functions, and there is no rationale for two isoforms. The current data identify a specific function for Insig-2. We show that eicosapentaenoic acid (EPA), a polyunsaturated fatty acid, inhibits fatty acid synthesis in human fibroblasts and rat hepatocytes by activating adenylate cyclase, which induces protein kinase A (PKA) to phosphorylate serine-106 in Insig-2. Phosphorylated Insig-2 inhibits the proteolytic processing of SREBP-1, thereby blocking fatty acid synthesis. Phosphorylated Insig-2 does not block the processing of SREBP-2, which activates cholesterol synthesis. Insig-1 lacks serine-106 and is not phosphorylated at this site. EPA inhibition of SREBP-1 processing was reduced by the replacement of serine-106 in Insig-2 with alanine or by treatment with KT5720, a PKA inhibitor. Inhibition did not occur in mutant human fibroblasts that possess Insig-1 but lack Insig-2. These data provide an Insig-2-specific mechanism for the long-known inhibition of fatty acid synthesis by polyunsaturated fatty acids.

Indexed as

Cyclic AMP-Dependent Protein KinasesFibroblastsIntracellular Signaling Peptides and ProteinsMembrane ProteinsSterol Regulatory Element Binding Protein 1AnimalsEicosapentaenoic AcidFatty AcidsFatty Acids, UnsaturatedHepatocytesHumansPhosphorylationRatsSterol Regulatory Element Binding Protein 2Cyclic AMP-Dependent Protein KinasesEicosapentaenoic AcidFatty AcidsFatty Acids, UnsaturatedINSIG1 protein, humanINSIG2 protein, humanIntracellular Signaling Peptides and ProteinsMembrane ProteinsSREBF1 protein, humanSterol Regulatory Element Binding Protein 1Sterol Regulatory Element Binding Protein 2cyclic AMPfatty acid synthesismammalian cellsphosphorylated Insig-2SREBP-1

Identifiers

PMID39145929
PMCPMC11348305

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.